Astrazeneca PLC (AZN): Price and Financial Metrics


Astrazeneca PLC (AZN): $55.05

0.55 (+1.01%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AZN POWR Grades


  • AZN scores best on the Quality dimension, with a Quality rank ahead of 89.39% of US stocks.
  • The strongest trend for AZN is in Momentum, which has been heading down over the past 206 days.
  • AZN ranks lowest in Momentum; there it ranks in the 7th percentile.

AZN Stock Summary

  • AZN has a higher market value than 98.51% of US stocks; more precisely, its current market capitalization is $144,524,826,512.
  • In terms of twelve month growth in earnings before interest and taxes, Astrazeneca Plc is reporting a growth rate of 87.89%; that's higher than 83.98% of US stocks.
  • In terms of volatility of its share price, AZN is more volatile than just 2.5% of stocks we're observing.
  • Stocks that are quantitatively similar to AZN, based on their financial statements, market capitalization, and price volatility, are BMY, AMGN, UNP, LIN, and CAT.
  • Visit AZN's SEC page to see the company's official filings. To visit the company's web site, go to www.astrazeneca.com.

AZN Stock Price Chart Interactive Chart >

Price chart for AZN

AZN Price/Volume Stats

Current price $55.05 52-week high $64.94
Prev. close $54.50 52-week low $46.48
Day low $54.43 Volume 7,311,700
Day high $55.22 Avg. volume 10,626,654
50-day MA $50.85 Dividend yield 3.38%
200-day MA $52.56 Market Cap 144.48B

Astrazeneca PLC (AZN) Company Bio


AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.

AZN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$55.05$45.91 -14%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Astrazeneca Plc. To summarize, we found that Astrazeneca Plc ranked in the 52th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Astrazeneca Plc, consider:

  • Astrazeneca Plc's weighted average cost of capital (WACC) is 9%; for context, that number is higher than merely 13.88% of tickers in our DCF set.
  • Relative to other stocks in its sector (Healthcare), Astrazeneca Plc has a reliance on debt greater than 69.07% of them.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-16%
1%-15%
2%-14%
3%-14%
4%-13%
5%-12%

Want more companies with a valuation profile/forecast similar to that of Astrazeneca Plc? See OFIX, PBH, IART, LMAT, and ITGR.


AZN Latest News Stream


Event/Time News Detail
Loading, please wait...

AZN Latest Social Stream


Loading social stream, please wait...

View Full AZN Social Stream

Latest AZN News From Around the Web

Below are the latest news stories about Astrazeneca Plc that investors may wish to consider to help them evaluate AZN as an investment opportunity.

2 Hyper-Growth Blue Chips For A Rich Retirement

Photo by RgStudio/E+ via Getty ImagesThere are many ways to earn strong returns on Wall Street, tailored to almost any specific goal, need, or risk profile. For traders, momentum, when done in a disciplined fashion, is the ideal strategy. For long-term investors, smaller companies, value, low volatility, dividend growth, equal...

Dividend Sensei on Seeking Alpha | May 13, 2021

CDC approves those fully vaccinated to largely ditch masks indoors

Yahoo Finance’s Anjalee Khemlani reports the latest updates on the coronavirus.

Yahoo | May 13, 2021

UPDATE 1-Quebec stops offering first doses of AstraZeneca vaccine

The Canadian province of Quebec will no longer offer first doses of the AstraZeneca COVID-19 vaccine as of Thursday, but will offer second doses using current supplies and future deliveries, the province's health ministry said in a release. Most provinces made similar announcements on Monday and Tuesday, mainly citing concerns about supply, though officials in Ontario and Nova Scotia said the move was also based on a rise in the incidence of rare blood clots linked to the vaccine. Canada's vaccine supply has expanded significantly in recent weeks, mostly thanks to shipments from Pfizer.

Yahoo | May 13, 2021

UK Study Answers Question If Two Doses Of COVID-19 Vaccines Can Be Mix-Matched?

Preliminary data from a U.K. clinical trial testing the benefits of mixing and matching COVID-19 vaccines showed that participants who received a mixed schedule of vaccines incurred more frequent reactions than those on standard non-mixed schedules and reports CNBC. What Happened: The trial named the Com-Cov study led by the University of Oxford and is examining the immune responses of trial participants given a dose of the Oxford-AstraZeneca Plc (NASDAQ: AZN) vaccine followed by the Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) shot and vice versa. The study aims to evaluate the feasibility of mixing and matching COVID-19 vaccines and whether this could be a viable route to increase the flexibility of vaccination campaigns. Some of the reactions reported among participants receiv...

Yahoo | May 13, 2021

Global tally of COVID-19 cases tops 160 million as U.S. gears up to vaccinate 12- to 15-year-olds

The global tally of confirmed cases of the coronavirus-borne illness COVID-19 climbed above 160 million on Thursday, as the U.S. braced for the start of a vaccination program for 12- to 15-year-olds after an authorization from the nation's main public health agency.

Yahoo | May 13, 2021

Read More 'AZN' Stories Here

AZN Price Returns

1-mo 10.45%
3-mo 8.51%
6-mo -2.25%
1-year 5.66%
3-year 66.17%
5-year 130.55%
YTD 12.20%
2020 3.06%
2019 35.58%
2018 13.77%
2017 33.10%
2016 -15.90%

AZN Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full AZN Dividend History

Continue Researching AZN

Here are a few links from around the web to help you further your research on Astrazeneca Plc's stock as an investment opportunity:

Astrazeneca Plc (AZN) Stock Price | Nasdaq
Astrazeneca Plc (AZN) Stock Quote, History and News - Yahoo Finance
Astrazeneca Plc (AZN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8246 seconds.